Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KHK | P50053 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345764 | 0.86 | RAB9A (0.51) | HTTKDM4EALDH1A1MAPTMAPK1 | |
| SCHEMBL3340223 | 0.85 | NPSR1 (0.56) | POLBHTTKMT2AKDM4EALDH1A1 | |
| SCHEMBL3341397 | 0.75 | MAPT (0.54) | HTTKDM4EMAPTMAPK1ADRB2 | |
| SCHEMBL4433890 | 0.74 | ADRB2 (0.51) | POLBHTTKMT2AKDM4EHPGD | |
| SCHEMBL27978531 | 0.74 | ADRB2 (0.58) | POLBHTTKMT2AALDH1A1MAPT | |
| SCHEMBL3342327 | 0.73 | MAPT (0.70) | POLBKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL14970183 | 0.73 | KMT2A (0.73) | LRRK2POLBHTTKMT2AALDH1A1 | |
| SCHEMBL14964955 | 0.72 | POLB (0.49) | POLBHTTKMT2AKHKADRB2 | |
| SCHEMBL1900199 | 0.72 | MAPK1 (0.55) | PRKDCPOLBHTTKMT2AMAPT | |
| SCHEMBL3083019 | 0.71 | MAPK1 (0.52) | POLBHTTKMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | LRRK2 1761/4885PRKDC 2250/4885POLB 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.